Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omrix claims US first for fibrin sealant:

This article was originally published in Clinica

Executive Summary

Omrix biopharmaceuticals has launched in the US what it claims to be the country's first commercially available liquid fibrin sealant that does not include any animal-derived components. The product, called Crosseal, is approved by the FDA as an adjunct to haemostasis in liver surgery. It requires no reconstitution and can be prepared for use in less than a minute, says the Brussels, Belgium-based firm. The sealant is being sold in the US by the American Red Cross Plasma Services, which formed a long-term marketing and distribution deal with Omrix earlier this year. Omrix markets a similar product, Quixil, in Europe, Latin America and Israel.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel